• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

筛查预防宫颈癌:挪威形态学的长期发病趋势。

Cervical cancer prevented by screening: Long-term incidence trends by morphology in Norway.

机构信息

Cancer Registry of Norway, Oslo, Norway.

出版信息

Int J Cancer. 2015 Oct 1;137(7):1758-64. doi: 10.1002/ijc.29541. Epub 2015 Apr 11.

DOI:10.1002/ijc.29541
PMID:25833121
Abstract

Both major morphologic types of cervical cancer, squamous cell carcinoma (SCC) and adenocarcinoma (AC), are causally related to persistent infection with high-risk human papillomavirus (hrHPV), but screening has primarily been effective at preventing SCC. We analysed incidence trends of cervical cancer in Norway stratified by morphologies over 55 years, and projected SCC incidence in the absence of screening by assessing the changes in the incidence rate of AC. The Cancer Registry of Norway was used to identify all 19,530 malignancies in the cervix diagnosed in the period 1956-2010. The majority of these (82.9%) were classified as SCCs, 10.5% as ACs and the remaining 6.6% were of other or undefined morphology. By joint-point analyses of a period of more than five decades, the average annual percentage change in the age-standardised incidence was -1.0 (95%CI: -2.1-0.1) for cervical SCC, 1.5 (95%CI:1.1-1.9) for cervical AC and -0.9 (95%CI: -1.4 to -0.3) for cervical cancers of other or undefined morphology. The projected age-standardised incidence rate of cervical SCC in Norway, assuming no screening, was 28.6 per 100,000 woman-years in 2010, which compared with the observed SCC rate of 7.3 corresponds to an estimated 74% reduction in SCC or a 68% reduction due to screening in the total cervical cancer burden. Cytology screening has impacted cervical cancer burden more than suggested by the overall observed cervical cancer incidence reduction since its peak in the mid-1970s. The simultaneous substantial increase in cervical adenocarcinoma in Norway is presumably indicative of an increase in exposure to HPV over time.

摘要

两种主要的宫颈癌形态学类型,鳞状细胞癌(SCC)和腺癌(AC),都与持续性感染高危型人乳头瘤病毒(hrHPV)有关,但筛查主要在预防 SCC 方面有效。我们分析了挪威 55 年来宫颈癌形态学的发病趋势,并通过评估 AC 发病率的变化来预测在没有筛查的情况下 SCC 的发病率。挪威癌症登记处用于确定 1956-2010 年期间诊断的 19530 例宫颈恶性肿瘤。其中大多数(82.9%)被归类为 SCC,10.5%为 AC,其余 6.6%为其他或未定义形态。通过对超过五十年的一个时期的联合点分析,宫颈 SCC 的年龄标准化发病率的平均年变化率为-1.0(95%CI:-2.1-0.1),宫颈 AC 为 1.5(95%CI:1.1-1.9),宫颈其他或未定义形态的癌症为-0.9(95%CI:-1.4 至-0.3)。假设没有筛查,挪威 2010 年宫颈 SCC 的年龄标准化发病率预计为 28.6/10 万妇女年,与观察到的 7.3 相比,预计 SCC 减少 74%,或总宫颈癌负担减少 68%,这归因于筛查。细胞学筛查对宫颈癌负担的影响比自 20 世纪 70 年代中期达到峰值以来观察到的宫颈癌总发病率下降所表明的更为显著。同时,挪威宫颈腺癌的大量增加大概表明随着时间的推移 HPV 暴露的增加。

相似文献

1
Cervical cancer prevented by screening: Long-term incidence trends by morphology in Norway.筛查预防宫颈癌:挪威形态学的长期发病趋势。
Int J Cancer. 2015 Oct 1;137(7):1758-64. doi: 10.1002/ijc.29541. Epub 2015 Apr 11.
2
Long-term incidence trends of HPV-related cancers, and cases preventable by HPV vaccination: a registry-based study in Norway.人乳头瘤病毒相关癌症的长期发病趋势以及可通过人乳头瘤病毒疫苗预防的病例:挪威一项基于登记处的研究
BMJ Open. 2018 Feb 23;8(2):e019005. doi: 10.1136/bmjopen-2017-019005.
3
A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment.一项关于鳞状细胞癌和腺癌筛查的瑞典纵向研究:有效性和过度治疗的证据。
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2641-8. doi: 10.1158/1055-9965.EPI-07-0278.
4
Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide.全球范围内子宫颈鳞状细胞癌和腺癌的发病率及死亡率趋势
Asian Pac J Cancer Prev. 2009 Oct-Dec;10(4):645-50.
5
Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening.13个欧洲国家宫颈鳞状细胞癌发病率趋势:风险变化及筛查的影响
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):677-86. doi: 10.1158/1055-9965.EPI-04-0569.
6
Changing incidence of invasive adenocarcinoma of the uterine cervix in East Anglia.东安格利亚地区子宫颈浸润性腺癌发病率的变化
J Med Screen. 1997;4(1):40-3. doi: 10.1177/096914139700400112.
7
Changes in cervical cancer incidence after three decades of screening US women less than 30 years old.对30岁以下美国女性进行三十年筛查后宫颈癌发病率的变化。
Obstet Gynecol. 2003 Oct;102(4):765-73. doi: 10.1016/s0029-7844(03)00696-3.
8
Cervical adenocarcinoma: moving towards better prevention.宫颈腺癌:迈向更好的预防。
Vaccine. 2011 Nov 15;29(49):9148-58. doi: 10.1016/j.vaccine.2011.09.115. Epub 2011 Oct 6.
9
Screening and adenocarcinoma of the cervix.宫颈癌的筛查与腺癌
Int J Cancer. 2009 Aug 1;125(3):525-9. doi: 10.1002/ijc.24410.
10
Trends in cancer of the cervix uteri in Sweden following cytological screening.瑞典宫颈细胞学筛查后子宫颈癌的发病趋势。
Br J Cancer. 1999 Sep;81(1):159-66. doi: 10.1038/sj.bjc.6690666.

引用本文的文献

1
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination.人乳头瘤病毒相关癌症的过去、现在和未来的流行病学:走向预防和消除。
Nat Rev Clin Oncol. 2024 Jul;21(7):522-538. doi: 10.1038/s41571-024-00904-z. Epub 2024 May 17.
2
Divergent effects of switching from cytology to HPV-based screening in the Nordic countries.细胞学筛查向 HPV 为基础的筛查转变在北欧国家的不同影响。
Eur J Public Health. 2024 Apr 3;34(2):354-360. doi: 10.1093/eurpub/ckad225.
3
Triage Value of Cervical Exfoliated Cell DNA Ploidy Analysis in Cervical High-Risk Human Papillomavirus-Positive Women.
宫颈脱落细胞 DNA 倍体分析在 HPV 高危型阳性妇女宫颈病变筛查中的应用价值。
J Low Genit Tract Dis. 2023 Oct 1;27(4):331-336. doi: 10.1097/LGT.0000000000000757. Epub 2023 Aug 16.
4
Strategies to eliminate cervical cancer in China.中国消除宫颈癌的策略。
Front Oncol. 2023 Jun 2;13:1105468. doi: 10.3389/fonc.2023.1105468. eCollection 2023.
5
Unpacking the Lay Epidemiology of Cervical Cancer: A Focus Group Study on the Perceptions of Cervical Cancer and Its Prevention among Women Late for Screening in Norway.剖析宫颈癌的大众流行病学:一项针对挪威筛查延迟女性对宫颈癌及其预防认知的焦点小组研究。
Healthcare (Basel). 2023 May 15;11(10):1441. doi: 10.3390/healthcare11101441.
6
Cervical cancer screening history among women diagnosed with cervical cancer in Estonia 2017-18.2017-18 年爱沙尼亚被诊断患有宫颈癌的女性的宫颈癌筛查史。
Eur J Public Health. 2023 Feb 3;33(1):64-68. doi: 10.1093/eurpub/ckac176.
7
Malignancies among newly diagnosed systemic lupus erythematosus patients and their survival.新诊断的系统性红斑狼疮患者的恶性肿瘤及其生存情况。
Lupus. 2022 Dec;31(14):1750-1758. doi: 10.1177/09612033221131501. Epub 2022 Oct 6.
8
HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial.挪威长期未参加宫颈癌筛查人群中 HPV 自我采样:一项实用随机对照试验。
Br J Cancer. 2022 Nov;127(10):1816-1826. doi: 10.1038/s41416-022-01954-9. Epub 2022 Aug 23.
9
Cervical cancer mortality in Norway according to screening attendance and age.挪威宫颈癌死亡率与筛查参与率及年龄的关系。
Acta Obstet Gynecol Scand. 2022 Sep;101(9):952-959. doi: 10.1111/aogs.14402. Epub 2022 Jun 11.
10
Time Trends for Incidence and Net Survival of Cervical Cancer in Sweden 1960-2014-A Nationwide Population-Based Study.1960-2014 年瑞典宫颈癌发病率和净生存率的时间趋势:一项全国基于人群的研究。
Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1572-1581. doi: 10.1158/1055-9965.EPI-21-1323.